Clinical Trials in Acute Lymphoblastic Leukaemia (ALL)


Trial Name


Trial Summary






The aims of this trial are to see if changing the standard treatment for children and young people with ALL or LBL will reduce side effects and help stop their disease from coming back. People aged 1 – 24 years old are eligible.





The aim of this study is to find a standard treatment for ALL in adults over the age of 60. Researchers can then use this in the future as a comparison when looking at any new treatments in clinical trials.



This trial compares selumetinib and dexamethasone for patients diagnosed with ALL


A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission